download
FREE KOL List
    • KOL
    • KOLs Community
    • Ovarian
    • Ovarian Cancer
    • Samuel Chi‐ho Mok
    • Samuel Chi‐ho Mok

      Samuel Chi‐ho Mok

      Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;, whu2@mdanderson.org, (W.H.);, ...

       

       

      KOL Resume for Samuel Chi‐ho Mok

      Year
      2021

      Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;, (W.H.);, (L.Z.);, (S.F.-B.);, (H.T.C.);, (T.-L.Y.);, (P.T.S.);, (K.H.L.);, (S.C.M.)

      The University of Texas MD Anderson Cancer Center, Houston, TX, United States

      2020

      Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;, (S.Y.K.);, (K.K.W.);, (P.T.S.);, (K.H.L.)

      The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at Houston, 77030, Houston, TX, USA

      2019

      The University of Texas MD Anderson Cancer Center, Houston, TX

      2018

      Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;, (T.-L.Y.);, (C.C.T.);, (C.S.L.);, (C.-L.A.Y.);, (M.S.T.);, (K.H.L.);, (R.S.F.);, (K.-K.W.)

      The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.

      2017

      Department of Gynecologic Oncology, and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

      The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, USA.

      2016

      Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;, (T.L.Y.);, (C.S.L.)

      2015

      The University of Texas MD Anderson Cancer Center, Houston, TX, USA

      2014

      The University of Texas MD Anderson Cancer Center Department of Gynecologic Oncology and Reproductive Medicine Houston Texas

      2013

      Cancer Biology Program, The University of Texas at Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA

      Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America

      2012

      Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

      2011

      Brigham and Women's Hospital, Harvard School of Public Health, Boston, Massachusetts, United States of America

      Authors' Affiliations: Departments of Gynecologic Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      2010

      Authors' Affiliations: Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Pathology, Brigham and Women's Hospital and Dana-Farber Harvard Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; and Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

      2009

      Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

      Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

      2008

      Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

      Boston University School of Medicine (M.E.L.) and Brigham and Women's Hospital (S.M.) — both in Boston

      2007

      Department of Obstetrics, Gynecology, and Reproductive Biology, Laboratory of Gynecologic Oncology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

      Gillette Center for Women's Cancer, Dana-Farber Harvard Cancer Center, Boston, MA

      From the Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

      2006

      Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

      Laboratory of Gynecology Oncology, Brigham and Women's Hospital, Harvard Medical School, USA

      2005

      Departments of Obstetrics, Gynecology and Reproductive Biology and

      Osaka City Gen Hosp, Osaka, Japan; Univ of Tokyo, Tokyo, Japan; Tohoku Univ Graduate Sch of Medicine, Sendai, Japan; National Cancer Institute, Rockville, MD; Brigham & Women’s Hosp, Boston, MA

       

       

      Samuel Chi‐ho Mok: Influence Statistics

      Sample of concepts for which Samuel Chi‐ho Mok is among the top experts in the world.
      Concept World rank
      erbeta skov3 #1
      investigation mir155hg expression #1
      elf3 tumor #1
      skov3 monolayer su11274 #1
      piicontaining transcripts #1
      microinjection e85 #1
      malignancy progression #1
      microdissected serous #1
      nonmalignant ovaries #1
      brca2 primary cultures #1
      exon ispecific rtpcr #1
      knockdown xdab2 expression #1
      s100a7 protein plasma #1
      hdab2 loss #1
      somites myogenic markers #1
      ishp1 expression #1
      dab2 protein mouse #1
      188 unbalanced translocations #1
      impedance skov3 #1
      eec foxc1 #1
      new technologies identification #1
      invasion real time #1
      expression doc2 #1
      highly metastatic skov3 #1
      identified multiple lncrnas #1
      highly dysregulated mirnas #1
      recurrent interstitial deletion #1
      hdab2 expression #1
      mdamb468 levels #1
      epithelium e85 #1
      proteomic screening study #1
      strongest dab2 expression #1
      underlying adherent cells #1
      impedance 4 khz #1
      skov3 cell mutation #1
      dab2 e85 #1
      sporadic ovarian tumors #1
      omental microenvironment #1
      exon piicontaining transcripts #1
      immortalized hose #1
      1970 lncrnas #1
      secretion t47d #1
      investigation primary tumors #1
      16 borderline #1
      xenopus embryos vivo #1
      serous electrophoresis gel #1
      myogenic markers somites #1
      hdab2 tumor suppressor #1
      rescued sparc #1
      outstanding candidate review #1

       

      Prominent publications by Samuel Chi‐ho Mok

      KOL-Index: 16175

      BACKGROUND: When ovarian carcinoma is diagnosed in stage I, up to 90% of patients can be cured with surgery and currently available chemotherapy. At present, less than 25% of cases are diagnosed at this stage. To increase the fraction of ovarian cancers detected at an early stage, screening strategies have been devised that utilize a rising serum CA125 level to trigger the performance of transvaginal sonography. One limitation of CA125 as an initial step in such a screening strategy is ...

      Known for Ovarian Cancers | Ca125 Expression | Neoplasm Biomarkers | Serum Markers | Early Stage
      KOL-Index: 16093

      Germline mutations of BRCA1 and BRCA2 predispose to hereditary breast, ovarian, and possibly prostate cancer, yet structural mutations in these genes are infrequent in sporadic cancer cases. To better define the involvement of these genes in sporadic cancers, we characterized expression levels of BRCA1 and BRCA2 transcripts in cancer cell lines derived from neoplasms of the ovary, prostate, and breast and compared them with those expressed in primary cultures of normal epithelial cells ...

      Known for Breast Cancer | Brca1 Brca2 | Neoplastic Genes | Altered Expression | Exon 12
      KOL-Index: 16057

      BACKGROUND: We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer.

      METHODS: We measured messenger RNA (mRNA) levels of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a quantitative reverse-transcriptase-polymerase-chain-reaction assay, and compared the results with clinical outcomes. Validation was performed with the use of published microarray data from cohorts of patients with ovarian, breast, and lung ...

      Known for Ovarian Cancer | Dicer Drosha | Messenger Rna | Hazard Ratio | Neoplastic Humans
      KOL-Index: 15160

      Bcl-2 and p53 gene products have been both linked to cell death by apoptosis. In the present study, we examined the relationship of Bcl-2 and p53 protein expression, p53 mutation and apoptosis in normal human ovaries and different types of human ovarian epithelial tumors by immunohistochemical localization, in situ terminal transferase-mediated dUTP nick end labeling and polymerase chain reaction-single strand conformation polymorphism. It was found that Bcl-2 expressed strongly in the ...

      Known for Protein Expression | Epithelial Ovarian | P53 Mutation | Malignant Tumors | Normal Ovaries
      KOL-Index: 14746

      Our understanding of the roles played by sex hormones in ovarian carcinogenesis has been limited by a lack of data concerning the mode of sex hormone action in human ovarian surface epithelial (HOSE) cells, the tissue of origin of >90% of ovarian cancers. We have compared the relative abundance of estrogen receptor (ER)alpha, ERbeta, progesterone receptor (PR), and androgen receptor (AR) mRNA in four primary cultures of HOSE cells obtained from postmenopausal women to those found in late ...

      Known for Estrogen Receptor | Epithelial Cells | Eralpha Erbeta | Malignant Ovarian | Neoplastic Humans
      KOL-Index: 14320

      TGF-β has limited effects on ovarian cancer cells, but its contributions to ovarian tumor growth might be mediated through elements of the tumor microenvironment. In the present study, we tested the hypothesis that TGF modulates ovarian cancer progression by modulating the contribution of cancer-associated fibroblasts (CAF) that are present in the microenvironment. Transcriptome profiling of microdissected stromal and epithelial components of high-grade serous ovarian tumors and ...

      Known for Tumor Microenvironment | Ovarian Cancer | Transforming Growth Factor | Tgf Β | Vcan Expression
      KOL-Index: 13881

      BACKGROUND: Screening biomarkers for ovarian cancer are needed because of its late stage at diagnosis and poor survival. We used microarray technology to identify overexpressed genes for secretory proteins as potential serum biomarkers and selected prostasin, a serine protease normally secreted by the prostate gland, for further study.

      METHODS: RNA was isolated and pooled from three ovarian cancer cell lines and from three normal human ovarian surface epithelial (HOSE) cell lines. ...

      Known for Ovarian Cancer | Microarray Technology | Serum Marker | Neoplasm Sensitivity | Messenger Rna
      KOL-Index: 13623

      OBJECTIVE: To determine the frequency of BRCA1 mutations 185delAG and 5382insC and BRCA2 mutation 6174delT in Jewish women with ovarian cancer and in matched controls in a population-based study.

      METHODS: Forty-eight Jewish women with epithelial ovarian cancer (32 invasive and 16 borderline) and 33 Jewish control subjects were obtained from a population-based, case-control study of ovarian cancer in eastern Massachusetts and New Hampshire. Mutational analysis on exons 2 and 20 of BRCA1 ...

      Known for Brca2 Mutations | Jewish Women | Ovarian Cancer | Female Genes | Mutational Analysis
      KOL-Index: 13485

      OBJECTIVE: Our purpose was to investigate the expression of matrix metalloproteinases (MMPs) in gestational trophoblastic diseases and normal first-trimester placenta.

      METHODS: Paraffin sections of 16 partial moles, 25 complete moles, 10 gestational choriocarcinomas, and 11 normal first-trimester placentas were studied immunohistochemically for expression of MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, and tissue inhibitor of metalloproteinase-1 (TIMP-1).

      RESULTS: Nine (90.0%) of the ...

      Known for Normal Placenta | Matrix Metalloproteinases | Extravillous Trophoblast | Choriocarcinoma Expression | Tissue Inhibitor
      KOL-Index: 13479

      Secreted protein acidic and rich in cysteine (SPARC) is an extracellular Ca(2+)-binding matricellular glycoprotein that associates with cell populations undergoing migration, morphogenesis, and differentiation. Studies on endothelial cells have established that its principal functions in vitro are counteradhesion and antiproliferation. The mechanism(s) underlying these antitumor effects is unknown. In this study, we showed that SPARC expression in ovarian cancer cells is inversely ...

      Known for Cancer Cells | Secreted Protein | Cysteine Sparc | Neoplastic Humans | Expression Regulation
      KOL-Index: 12952

      Ovarian tumors of low malignant potential and low-grade ovarian serous carcinomas are thought to represent different stages on a tumorigenic continuum and to develop along pathways distinct from high-grade ovarian serous carcinoma. We performed gene expression profiling on three normal human ovarian surface epithelia samples, and 10 low-grade and 10 high-grade ovarian serous carcinomas. Analysis of gene expression profiles of these samples has identified 80 genes upregulated and 232 ...

      Known for Pax2 Expression | Ovarian Serous | Low Grade | Malignant Potential | Upregulated Genes
      KOL-Index: 12516

      OBJECTIVES: We have previously described that bioactive lysophospholipids-lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P), and sphingosylphosphorylcholine (SPC)-are present in ascitic fluids from patients with ovarian cancer. To understand the role of these lipids in ovarian cancer, we investigated the effects of these lipids on interleukin-8 (IL-8) production in ovarian cancer cells. IL-8 is a proinflammatory and proangiogenic factor, which is potentially involved in ovarian ...

      Known for Ovarian Cancer Cells | Lpa S1p | Neoplastic Humans | Lysophospholipids Increase | Mrna Levels

      Key People For Ovarian Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #3
      Ignace B P Vergote
      ovarian cancer neoadjuvant chemotherapy advisory consultancy
      #4
      Robert C Bast
      ovarian cancer early detection bone marrow
      #5
      Beth Young Karlan
      ovarian cancer brca2 mutation brca1 genes
      #6
      Anil K Sood
      ovarian cancer tumor growth gene expression

      Samuel Chi‐ho Mok:Expert Impact

      Concepts for whichSamuel Chi‐ho Mokhas direct influence:Ovarian cancer,  Normal placenta,  Complete mole,  Cancer cells,  Ovarian cancer cells,  Papillary serous carcinoma,  Epithelial ovarian,  Ovarian tumors.

      Samuel Chi‐ho Mok:KOL impact

      Concepts related to the work of other authors for whichfor which Samuel Chi‐ho Mok has influence:Ovarian cancer,  Gene expression,  Tumor microenvironment,  Cell proliferation,  Neoplastic humans.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;, whu2@mdanderson.org, (W.H.);, lzhang25@mdanderson.org, (L.Z.);, sferri@mdanderson.org, (S.F.-B.);, hcun@mdanders

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.